In a report issued on December 6, Tim Lugo from William Blair maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report). The company's shares closed last Monday at $139.16, close to its 52-week high of $151.51. According to TipRanks.com, Lugo is a 4-star analyst with an average return of 13.4% and a 45.9% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, BioMarin Pharmaceutical, and Eagle Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Pharmaceutical Holding Co with a $152.91 average price target, implying a 12.5% upside from current levels.
https://www.tipranks.com/news/blurbs/william-blair-remains-a-buy-on-biohaven-pharmaceutical-holding-co-bhvn?utm_source=advfn.com&utm_medium=referral
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Biohaven Pharmaceutical Charts.
Biohaven Pharmaceutical (NYSE:BHVN)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Biohaven Pharmaceutical Charts.